Innovative, Fundable, Early Stage Opportunities
Presentations from early-stage companies with innovative technologies and proven management. Click on the logo below to view the company’s presentation from the 2014 Life Sciences Summit™.
AgeneBio, Inc., Baltimore, MD: developing therapeutics with the potential to preserve and restore cognitive function affected by a number of neurodegenerative diseases, and their lead product candidate is being developed to slow progression of Alzheimer’s disease and improve patient memory. President & CEO Jerry McLaughlin – previously NuPathe, Merck and Endo Pharmaceuticals.
AiCure, New York, NY – Developed state-of-the-art facial recognition to automatically confirm medication adherence in clinical research. This form of virtual medication reconciliation reduces the risk of clinical trial failure by ensuring that the right patient is taking the right medication at the right time – without the need for direct human supervision. CEO Adam Hanina.
Amorsa Therapeutics, Inc., Littleton, MA: Developing a ketamine-based formulation that will deliver steady and sustained-release ketamine, as an adjuvant therapy with opioids, in an effective and convenient once-a-day tablet. CEO Joe Blanchard, MBA – previously Aushon BioSystems, Altus Pharmaceuticals, Genencor International, Decision Biomarkers, Akzo Nobel, DuPont/Conoco Chemicals.
BioMarker Strategies, Rockville, MD: BioMarker Strategies is a privately held Maryland-based company that has pioneered development of the SnapPath® Cancer Diagnostics System. SnapPath is the only automated system that generates purified populations of live cells from fresh unfixed solid tumor samples, and the only system that enables automated standardized ex vivo interrogation of live solid tumor cells. President & CEO Jerry Parrott – previously Human Genome Sciences, Bristol-Myers Squibb, American Hospital Supply and Walgreens.
Biometheus, LLC, Winchester, MA: Utilizing their placebo gene technology, developing a genetic test to predict placebo responders in clinical trials that has the potential to significantly reduce size, cost and duration of new drug development. CEO Gunther Winkler – previously Biogen Idec.
Cell Source (OTC: CLCS) Tel Aviv, Israel: Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. CEO Itamar Shimrat – previously First International Bank of Israel, McKinsey & Company, Mitchell Madison Group, Bain & Co.
Cloud Pharmaceuticals, Inc., Research Triangle Park, NC: Formerly TeraDiscoveries Inc., a bio pharmaceutical company utilizing their in-silico drug design platform, Inverse Design, which combines high-performance cloud computing, quantum chemistry, molecular mechanics, and statistical analysis, Cloud Pharmaceuticals provides a cost effective way to identify novel therapeutics in areas including cancer, inflammation, CNS disorders, and rare diseases. CEO Ed Addison – previously BioFortis, TeraDisc ConQuest Software, Powerize.com
Curtana Pharmaceuticals, Austin, TX: A privately-held, preclinical-stage biopharmaceutical company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma multiforme (GBM) and other brain cancers. CEO Gregory Stein, MD – previously Sova Pharmaceuticals, Inc., Genoptix, Opus Pharmaceuticals Uzima Bioscience.
Cyclica Inc, Toronto, Canada: A big data company that is developing indexed, multi-scale biological databases and software packages for the pharmaceutical and biotechnology industries. Their core technology is an innovative and proprietary data integration and drug testing platform – The Ligand Express™ Computing Environment – that is addressing the rising cost of R&D in drug discovery and low regulatory approval rates of pre-market pharmaceutical and biopharmaceutical products. Vice President, Finance Naheed Kurji – previously Bank of Montreal (BMO), TD Bank.
Cynvec LLC, New York, NY: An oncology focused biotechnology company founded to exploit the cancer killing ability of the the company’s proprietary oncolytic viral vector, sindbis. President & CEO Richard Purcell — previously ClinPro, SCP Communications, Kline and Company.
DiamiR Biosciences, Monmouth Junction, NJ: A molecular diagnostic company focused on developing noninvasive tests based on quantitative analysis of circulating organ-enriched microRNAs in plasma for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s disease, Parkinson’s disease, other neurodegenerative diseases, and cancer. CEO Kira Sheinerman – previously Burrill Securities, Rodman & Renshaw.
Formula Pharmaceuticals, Inc., Berwyn, PA: A privately-held, oncology drug development company advancing novel therapies to address critical unmet medical needs in cancer. COO Roland Turck – previously Bayer Healthcare.
Indi Molecular, Culver City, CA: A company developing a synthetic class of diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. PCCs offer the promise of improved selectivity, superior binding affinity, fully synthetic composition and a vastly low molecular weight compared to monoclonal antibodies. CEO Albert Luderer –previously bioMerieux.
Induce Biologics, Toronto, Canada: A regenerative medicine company developing bioimplants for bone regeneration. The lead product candidate, URIST™, is a novel implant that contains bone morphogenetic protein (BMP), and a proprietary carrier; this carrier provides a gradual, multi-phasic delivery of BMP. CEO and Clinical Advisor Cameron Clokie, DDS, PhD
Intensity Therapeutics, Westport, CT: A specialty pharmaceutical company whose mission is to extend the lives of cancer patients through the development of novel chemotherapeutic products that use advanced imaging, formulation science, drug delivery and immunology in new field of cancer treatment – in situ chemovaccination. CEO Lewis Bender – previously Interleukin Genetics, Emisphere Technologies.
Integene International, Developing a unique gene switch technology that results in permanent, directional establishment of a regenerated vasculature in patients with Critical Limb Ischemia (CLI). CEO Jim DeMesa, MD
Intezyne, Inc., Tampa, FL: A clinical-stage company whose lead compound is a Phase 2-ready first-in-class GRP78 suppressor, which has demonstrated significant potential in patients with neuroendocrine tumors. CFO Tim Coan – previously Deerfield Partners.
ioGenetics, Malvern, PA: Is developing novel first/best-in-class anti-infectives called “DBAF” (Directed Biocide® antibody fusions) to treat difficult infections such as MRSA and Strep. pneumoniae. President and CEO Shankar Musunuri, PhD, MBA – previously Nuron Biotech, Inc., Pfizer and Wyeth
Nanometics, Great Neck, NY: Developing a repurposed small molecule as an acute intravenous (IV) therapy for sickle cell crisis. Founder & CEO Steven Isaacman, PhD – previously designed and fabricated materials for the personal care and pharmaceutical industry.
Neurotez Inc., Bridgewater, NJ: Developing a Leptin product as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk. CEO Nikolaos Tezapsidis, PhD – previously Columbia University, New York University Medical School, Mount Sinai School of Medicine , Institute for Basic Research, Uniformed Services University of the Health Sciences, Imperial College of Science, Technology and Medicine.
Provista Diagnostics, Inc., New York, NY: Developing and commercializing diagnostic, prognostic and monitoring tests for cancers affecting women, through its proprietary platform. CEO David E. Reese, PhD – previously Brencourt Advisors, Alexea Consulting, LLC, Yorkville Advisors, LLC
Rgenix, New York, NY: Discovered novel metastasis therapeutic targets for several cancer sub-types and has generated first-in-class lead drug candidates. CEO David Darst – previously OrbiMed Advisors
Wellesley Pharmaceuticals, Newton, PA: Developed a novel combination therapy to treat nocturia, or excessive urination at night. President & CEO David Dill – previously IBM.
Zocere, Inc., Albuquerque, NM: Developing a patented technology for a derivative of the brain-specific STEP protein, tyrosine phosphatase, to commercialize novel therapeutics for neurological diseases, including stroke. CEO Wayne Laslie – previously Pfizer, Sanofi.